Background {#Sec1}
==========

Kaposi's sarcoma (KS) is a malignant neoplasm of lymphatic endothelial cells defined for the first time in 1872 \[[@CR1]\]. A Hungarian dermatologist, Moritz Kaposi, named it as "idiopathic multiple pigmented sarcoma", also known as "Kaposi's angiosarcoma" or "idiopathic multiple hemorrhagic sarcoma". KS is a systemic angiomatosis with malignant evolution, which is initially manifested as multiple vascular nodules in the skin and other organs \[[@CR2], [@CR3]\]. Classic Kaposi's sarcoma (CKS) mostly affects people of Mediterranean background and Jewish origin, Italy and Turkey being the countries with the highest frequency of the disease. CKS appears between the fifth and seventh decade of life and is more common in males than females with a ratio of 15 to 1.

The most frequent location is the lower extremities with cutaneous affectation and centripetal extension. Tumors and nodules can either be covered by normal skin, atrophic skin or ulcerated; some others may have a wart-like or fungal surface. The lesions can be painful, edematous and hemorrhagic, limiting patient ambulation. The damage may appear on internal organs or be only visceral without any cutaneous lesions. Despite the fact that any internal organ can be affected, it can also appear without cutaneous lesions and exclusive visceral affection. The affection of the lungs or lymph nodes it is not frequent. Death can be a consequence of generalized disease with cachexia, hemorrhage, or impairment of vital organs function by tumor growth \[[@CR4], [@CR5]\].

The following table shows a classification of the most common forms found in the current literature, which divides CKS into four stages \[[@CR6]\] (Table [1](#Tab1){ref-type="table"}).Table 1Staging of classic Kaposi's sarcomaLesionsLocationBehaviorEvolutionComplicationsI Nodules/maculesLegsNonaggressiveA - slow B - fastLymphedema lymphorrheaII PlaquesLegsLocally aggressiveA - slow B - fastHemorrhageIII Angiomatous plaques and nodulesLimbsLocally aggressiveA - slow B - fastFunctional damageIV Angiomatous plaques and nodulesLimbs, trunk, headDisseminatedB - fastUlcerationStages I and II are subdivide into:Group A: slow progressionGroup B: rapid progression with an increased number of plates/nodules or the extension that the nodules occupy in 3 months since the last scanStages III and IV present more gastrointestinal and visceral affectation

Case presentation {#Sec2}
=================

A 78-year-old Mexican man with no evidence of human immunodeficiency virus (HIV) infection presented with a history of two cardiac catheterizations, longstanding hypertension, high-risk prostate cancer treated with total androgenic blockage and radiation therapy (RT). Our patient also presented a painful widespread dermatosis with maculopapular, nodular, violaceous lesions on his legs and ulcerated lesions on his feet, limiting our patient's ambulation for a year (Fig. [1](#Fig1){ref-type="fig"}). In order to confirm the diagnosis of CKS, an incisional biopsy was performed on our patient; the result was non-HIV-associated CKS without immunosuppression (Fig. [2](#Fig2){ref-type="fig"}). The final diagnosis was: dispersed and aggressive stage IV CKS. Our patient was not a candidate for systemic therapy due to the comorbidities and the high toxicity risk. Radiotherapy was decided as the single treatment with the Clinac iX energy 6MV equipment (Varian Medical Systems, Inc., Palo Alto, CA, USA), using two fields of treatment and 100 % of the prescription dose, giving a total dose of 3000 cGy in 15 fractions, 200 cGy per fraction, and a bolus of 0.5 cm doses to the surface. An increase in electrons for his heels with a 0.5 cm depth from the skin was considered (Fig. [3](#Fig3){ref-type="fig"}).Fig. 1Cutaneous lesions affected the lower extremities in a symmetrical fashion, mainly heels and toes. Lesions reduced in size after treatment with radiation therapy. After 15 months of radiotherapy, a complete response was observed in his feet with improved mobility, complete disappearance of pain, and without significant toxicity Fig. 2Kaposi's sarcoma at low magnification. Kaposi's sarcoma is mainly composed of spindle cells separated by vascular channels Fig. 3Field of treatment with Clinac iX equipment, two field photon mode

Discussion {#Sec3}
==========

Treatment for classic Kaposi's sarcoma is mainly palliative. Multidisciplinary treatment methods with different responses are applied to CKS therapy such as intralesional interferon alpha, cryotherapy, hormone therapy, laser removal, systemic chemotherapy, infrared coagulation and radiotherapy depending on the clinical form \[[@CR7]\]. Radiotherapy is a useful method to improve the quality of life in patients with CKS and the response to treatment usually carries minimal toxicity \[[@CR8]\]. CKS is generally considered sensitive to radiation therapy with good palliative and esthetic results, demonstrated with doses greater than 20 Gy \[[@CR9]\]. In this sense in the literature, a standard dose of treatment is not mentioned; however, radiotherapy hypofractionation has demonstrated to have an impact in terms of recurrence-free survival, toxicity, and local control \[[@CR10]\]. For those patients with a limited life expectancy one fraction with 800 cGy has shown to provide successful outcomes \[[@CR11]\]. In this case, the dose of 30 Gy in sessions of 2 Gy per fraction in combination with electron therapy in the same dosage in the lesions had a complete response on his feet, along with the relief of symptoms and improvement in life quality of our patient.

Conclusions {#Sec4}
===========

It is uncommon to use radiation therapy as the single treatment in stage IV classic Kaposi's sarcoma, the efficacy of the treatment is shown in the impact in our patient's recurrence-free survival, local control, and palliation of patient symptoms.
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